ANDA 215458, held by Mankind Pharma. Omega-3-ACID Ethyl Esters.
As of Nov 22, 2026, ANDA 215458 (Omega-3-ACID Ethyl Esters), held by Mankind Pharma, was first approved by FDA on Nov 15, 2021, with 0 approved supplements and 0 published complete response letters.
Omega-3-acid ethyl esters capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules and should continue this diet during treatment with omega-3-acid ethyl esters capsules. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 15, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Omega-3-ACID Ethyl Esters1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS · capsule;oral | Omega-3-ACID Ethyl Esters | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters